한글목차

세계의 프로테아제 저해제 시장은 2024년에 69억 2,000만 달러로 평가되며, 2030년까지 CAGR 4.76%로 성장하며, 91억 5,000만 달러에 달할 것으로 예측됩니다. 프로테아제 억제제는 특정 바이러스의 복제 및 특정 질병의 진행에 필수적인 단백질 분해에 중요한 효소인 프로테아제의 활성을 억제하도록 설계된 치료제의 일종입니다. 이러한 억제제 세계 시장은 HIV/AIDS 및 C형 간염과 같은 바이러스 감염증 증가 추세와 보다 표적화된 화합물을 생성하는 생명공학 기술의 지속적인 발전으로 인해 크게 지원되고 있습니다.

주요 시장 성장 촉진요인

만성질환 및 감염성 질환의 유병률 증가는 세계 프로테아제 억제제 시장 수요 측면의 기본적인 촉진요인으로 작용하고 있습니다. 특히 인간면역결핍바이러스(HIV) 감염을 비롯한 전 세계 질병 부담 증가는 효과적인 치료 중재의 지속적인 개발과 보다 광범위한 접근을 요구하고 있습니다.

주요 시장 과제

약제 내성의 지속적인 출현은 세계 프로테아제 억제제 시장 확대에 큰 장벽이 되고 있습니다. 이 문제는 표적이 되는 바이러스나 병원체가 약물의 작용을 회피하는 메커니즘을 개발하므로 기존 치료제의 효능을 직접적으로 떨어뜨립니다.

주요 시장 동향

치료 용도의 다양화는 기존 항바이러스 적응증을 넘어 시장 범위를 확대하는 세계 프로테아제 억제제 시장의 중요한 동향입니다. 기존에는 HIV, C형 간염 등 질병 관리의 중심이었던 프로테아제 억제제는 현재 다양한 형태의 암, 염증성 질환, 신경질환 등 보다 광범위한 질환군에 대한 탐색 및 개발이 진행되고 있습니다.

목차

제1장 개요

제2장 조사 방법

제3장 개요

제4장 고객의 소리

제5장 세계의 프로테아제 저해제 시장 전망

• 시장 규모·예측
  • 금액별
• 시장 점유율·예측
  • 질환별(HIV/AIDS, C형 간염,α-1항트립신 결핍증, 유전성 혈관부종(HAE), 기타)
  • 용도별(병원·진료소, 연구기관·학술기관, 기타)
  • 지역별
  • 기업별(2024)
• 시장 맵

제6장 북미의 프로테아제 저해제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 프로테아제 저해제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 유럽 : 국가별 분석
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양지역프로테아제 저해제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 중동·아프리카프로테아제 저해제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트
  • 남아프리카공화국

제10장 남미의 프로테아제 저해제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 남미 : 국가별 분석
  • 브라질
  • 콜롬비아
  • 아르헨티나

제11장 시장 역학

• 촉진요인
• 과제

제12장 시장 동향과 발전

• 합병·인수
• 제품 출시
• 최근 동향

제13장 세계의 프로테아제 저해제 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• Boehringer Ingelheim International GmbH
• Cytoskeleton, Inc.
• Genentech, Inc.
• Merck & Co., Inc.
• Thermo Fisher Scientific, Inc.
• Kerry Group plc
• Mycorena AB
• Omega Protein Corporation

제16장 전략적 제안

제17장 조사회사 소개·면책사항

영문목차

The Global Protease Inhibitors Market, valued at USD 6.92 Billion in 2024, is projected to experience a CAGR of 4.76% to reach USD 9.15 Billion by 2030. Protease inhibitors constitute a class of therapeutic agents designed to obstruct the activity of proteases, enzymes essential for the cleavage of proteins critical to the replication of specific viruses and the progression of certain diseases. The global market for these inhibitors is largely supported by the increasing prevalence of viral infections, including HIV/AIDS and hepatitis C, coupled with ongoing advancements in biotechnology that yield more targeted compounds.

Key Market Drivers

The increasing prevalence of chronic and infectious diseases serves as a fundamental demand-side driver for the global protease inhibitors market. The escalating global burden of conditions, particularly human immunodeficiency virus HIV infection, necessitates continuous development and broader access to effective therapeutic interventions. Protease inhibitors remain crucial in HIV management.

Key Market Challenges

The persistent emergence of drug resistance represents a considerable impediment to the expansion of the Global Protease Inhibitors Market. This challenge directly diminishes the efficacy of current therapeutic agents, as target viruses and disease-causing agents develop mechanisms to circumvent drug action. Such evolution reduces the effective lifespan of existing protease inhibitor treatments and continuously drives the need for costly and prolonged research into novel compounds with new mechanisms of action.

Key Market Trends

The diversification of therapeutic applications represents a pivotal trend for the Global Protease Inhibitors Market, expanding its reach beyond established antiviral indications. Historically central to managing conditions like HIV and Hepatitis C, protease inhibitors are increasingly being explored and developed for a broader spectrum of diseases, including various forms of cancer, inflammatory disorders, and neurological conditions. This strategic broadening of focus is driven by a deeper mechanistic understanding of protease involvement in diverse pathological processes, leading to the identification of novel targets suitable for inhibition.

Key Market Players

• Boehringer Ingelheim International GmbH
• Cytoskeleton, Inc.
• Genentech, Inc.
• Merck & Co., Inc.
• Thermo Fisher Scientific, Inc.
• Kerry Group plc
• Mycorena AB
• Omega Protein Corporation

Report Scope:

In this report, the Global Protease Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Protease Inhibitors Market, By Disease indication:

• HIV/AIDS
• Hepatitis C
• Alpha-1 Antitrypsin Deficiency
• Hereditary Angioedema (HAE)
• Others

Protease Inhibitors Market, By End-Use:

• Hospitals & Clinics
• Research Laboratories and Academic Institutes
• Others

Protease Inhibitors Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Protease Inhibitors Market.

Available Customizations:

Global Protease Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Protease Inhibitors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease indication (HIV/AIDS, Hepatitis C, Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema (HAE), Others)
  • 5.2.2. By End-Use (Hospitals & Clinics, Research Laboratories and Academic Institutes, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Protease Inhibitors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease indication
  • 6.2.2. By End-Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Protease Inhibitors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease indication
      • 6.3.1.2.2. By End-Use
  • 6.3.2. Canada Protease Inhibitors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease indication
      • 6.3.2.2.2. By End-Use
  • 6.3.3. Mexico Protease Inhibitors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease indication
      • 6.3.3.2.2. By End-Use

7. Europe Protease Inhibitors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease indication
  • 7.2.2. By End-Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Protease Inhibitors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease indication
      • 7.3.1.2.2. By End-Use
  • 7.3.2. France Protease Inhibitors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease indication
      • 7.3.2.2.2. By End-Use
  • 7.3.3. United Kingdom Protease Inhibitors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease indication
      • 7.3.3.2.2. By End-Use
  • 7.3.4. Italy Protease Inhibitors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease indication
      • 7.3.4.2.2. By End-Use
  • 7.3.5. Spain Protease Inhibitors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease indication
      • 7.3.5.2.2. By End-Use

8. Asia Pacific Protease Inhibitors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease indication
  • 8.2.2. By End-Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Protease Inhibitors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease indication
      • 8.3.1.2.2. By End-Use
  • 8.3.2. India Protease Inhibitors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease indication
      • 8.3.2.2.2. By End-Use
  • 8.3.3. Japan Protease Inhibitors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease indication
      • 8.3.3.2.2. By End-Use
  • 8.3.4. South Korea Protease Inhibitors Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease indication
      • 8.3.4.2.2. By End-Use
  • 8.3.5. Australia Protease Inhibitors Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease indication
      • 8.3.5.2.2. By End-Use

9. Middle East & Africa Protease Inhibitors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease indication
  • 9.2.2. By End-Use
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Protease Inhibitors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease indication
      • 9.3.1.2.2. By End-Use
  • 9.3.2. UAE Protease Inhibitors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease indication
      • 9.3.2.2.2. By End-Use
  • 9.3.3. South Africa Protease Inhibitors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease indication
      • 9.3.3.2.2. By End-Use

10. South America Protease Inhibitors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease indication
  • 10.2.2. By End-Use
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Protease Inhibitors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease indication
      • 10.3.1.2.2. By End-Use
  • 10.3.2. Colombia Protease Inhibitors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease indication
      • 10.3.2.2.2. By End-Use
  • 10.3.3. Argentina Protease Inhibitors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease indication
      • 10.3.3.2.2. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Protease Inhibitors Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Boehringer Ingelheim International GmbH
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Cytoskeleton, Inc.
• 15.3. Genentech, Inc.
• 15.4. Merck & Co., Inc.
• 15.5. Thermo Fisher Scientific, Inc.
• 15.6. Kerry Group plc
• 15.7. Mycorena AB
• 15.8. Omega Protein Corporation

16. Strategic Recommendations

17. About Us & Disclaimer